Elsevier to Participate in SCOAP3 With the Journals Physics Letters B and Nuclear Physics B

Published on Wednesday, 18 July 2012 05:12 Written by TradersHuddle Staff

AMSTERDAM, July 18, 2012 /PRNewswire/ --

Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced that it is pleased to have the opportunity to participate in SCOAP³   (Sponsoring Consortium for Open Access Publishing in Particle Physics), a new model for open access publishing. Key SCOAP³ principles are perpetual open access, wide re-use licenses, and reduction and re-direction of subscription fees to centrally cover for article processing charges in journals carrying SCOAP³ content, with no charges to authors.

"After many years of intense preparations, we are excited to be a part of this important initiative," said Charon Duermeijer, Publishing Director and head of Elsevier's Physics journals. "Elsevier is looking forward to a close, fruitful and long-lasting collaboration with SCOAP3 and the High Energy Physics community."

Under SCOAP³ two well-established Elsevier journals -- Physics LettersB and Nuclear PhysicsB -- will change from a subscription based model into an open access model by the start of 2014. Both journals are fully focused on publications from the High Energy Physics field. Articles funded by SCOAP³ will be available open access in perpetuity, under a CC-BY license.  

"SCOAP³ is pleased that Physics Letters B and Nuclear Physics B participate in this initiative, as these journals have played since long an important role in High-Energy Physics literature," said Salvatore Mele, SCOAP3 project manager at CERN.

Acting for the benefit of SCOAP³, CERN conducted the tendering.  This open and competitive procedure took into account the quality of journals (as measured by Impact Factor), the quality of services provided (as measured by re-use licenses and delivery formats), and the unit price for publishing each article.



See the official SCOAP3 announcement here.

About Elsevier

Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include ScienceDirect, Scopus, Reaxys, MD Consult and Mosby's Nursing Suite, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai's Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Media contact

Tom Reller

Vice President, Global Corporate Relations, Elsevier

+1-215-239-3508

This e-mail address is being protected from spambots. You need JavaScript enabled to view it.

SOURCE Elsevier